Bio

Dr. Wu is a board-certified cardiologist at Stanford Health Care. He is also a clinical assistant professor in the Division of Cardiovascular Medicine. His areas of clinical focus include general and preventive cardiology with a particular interest in cardiac imaging. Dr. Wu has board certification in echocardiography, cardiovascular CT, and cardiac nuclear imaging.

Dr. Wu speaks fluent Chinese and Spanish and embraces racial, ethnic, and socioeconomic diversity in his clinical care. He has international clinical/research experiences in Italy and Mexico, and truly enjoys meeting and working with people from distinctive backgrounds.

Dr. Wu is passionate about clinical research. He has pursued scholarly work on the utilization of therapeutic drug monitoring for antihypertensive therapy and statins to help patients from low socioeconomic backgrounds improve their medication adherence. He is also involved in research on advanced cardiac imaging and has actively investigated the applications of cardiac CT in electrophysiology interventions.

Dr. Wu’s research has been published in peer-reviewed journals such as the International Journal of Cardiology and Journal of Vascular Surgery. He has presented his work at regional and national meetings, including the American Heart Association’s annual Scientific Sessions.

Dr. Wu is a member of the American College of Physicians, American Heart Association, and American Medical Association.

Clinical Focus

  • Cardiovascular Disease

Academic Appointments

Professional Education

  • Board Certification: National Board of Echocardiography, Adult Echocardiography (2022)
  • Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2023)
  • Board Certification, American Board of Internal Medicine, Cardiovascular Diseases (2023)
  • Board Certification, Certification Board of Cardiovascular Computed Tomography, Cardiovascular Computed Tomography (2023)
  • Cardiology Fellowship, University of California San Diego, CA (2023)
  • Board Certification, Certification Board of Nuclear Cardiology, Nuclear Cardiology (2023)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2020)
  • Residency, University of Texas Southwestern Medical Center, TX (2020)
  • Medical Education, University of Pittsburgh School of Medicine, PA (2017)
  • Bachelor of Science, University of Notre Dame, IN (2013)

Contact

  • Academic
    bryanwu@stanford.edu
    Department: Medicine - Med/Cardiovascular Medicine Position: Clinical Assistant Professor
  • Clinical (Primary)  San Jose Medical Group 2585 Good Samaritan Dr Internal Medicine San Jose, CA 95124 (408) 357-1265 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5406

All Publications

  • A large language model for complex cardiology care. Nature medicine O'Sullivan, J. W., Palepu, A., Saab, K., Weng, W. H., Amponsah, D. K., Cheng, E., Cheng, Y., Chu, E., Desai, Y., Elezaby, A., Fazal, M., Hussain, T., Jain, S. S., Kim, D. S., Lan, R., Li, J., Tang, W., Tapaskar, N., Parikh, V., Sandoval, R., Spencer-Bonilla, G., Wu, B., Kulkarni, K., Mansfield, P., Webster, D., Gottweis, J., Barral, J., Schaekermann, M., Tanno, R., Mahdavi, S. S., Natarajan, V., Karthikesalingam, A., Ashley, E., Tu, T. 2026

    Abstract

    The scarcity of subspecialist medical expertise poses a considerable challenge for healthcare delivery. This issue is particularly acute in cardiology, where timely, accurate management determines outcomes. We explored the potential of Articulate Medical Intelligence Explorer (AMIE), a large language model-based experimental medical artificial intelligence system, to augment clinical decision-making in this challenging context. We conducted a randomized controlled trial comparing large language model-assisted care with the usual care of complex patients suspected of having a genetic cardiomyopathy, and we curated a real-world dataset of complex cases from a subspecialist cardiology practice. Nine participating general cardiologists were provided with access to both clinical text reports and raw diagnostic data-including electrocardiograms, echocardiograms, cardiac magnetic resonance imaging scans and cardiopulmonary exercise testing-and were randomized to manage these cases, either with or without assistance from AMIE. We developed a ten-domain evaluation rubric used by three blinded subspecialists to evaluate the quality of triage, diagnosis and management. In our randomized controlled trial with retrospective patient data, subspecialists favored large language model-assisted responses overall, and for the management plan and diagnostic testing domains, with the remaining domains considered a tie. Overall, subspecialists preferred AMIE-assisted cardiology assessments 46.7% of the time, compared with 32.7% for cardiologists alone (P = 0.02), with 20.6% rated as a tie. Subspecialists also quantified errors, extra and missing content, reasoning and potential bias. Cardiologists alone had more clinically significant errors (24.3% versus 13.1%, P = 0.033) and more missing content (37.4% versus 17.8%, P = 0.0021) than cardiologists assisted by AMIE. Lastly, cardiologists who used AMIE reported that AMIE helped their assessment more than half the time (57.0%) and saved time in 50.5% of cases.

    View details for DOI 10.1038/s41591-025-04190-9

    View details for PubMedID 41652123

    View details for PubMedCentralID 10564921

  • High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism Wu, B., Nieman, K., Sandoval, R. 2025

    Abstract

    Pericoronary adipose tissue (PCAT) attenuation, assessed by coronary computed tomography angiography (CCTA), is a biomarker of coronary inflammation. Mean PCAT attenuation ≥ -70.5 Hounsfield Units (HU) corresponds to elevated inflammation and a higher future risk of myocardial infarction. While statins are known to possess anti-inflammatory properties, the impact of statin intensity on vascular inflammation remains underexplored in patients with type 2 diabetes mellitus (T2DM) and coronary atherosclerosis. We aim to evaluate whether high-intensity statins are associated with lower PCAT attenuation in this high-risk cohort.We retrospectively analysed 203 CCTAs performed at our institution between 1/1/2019 and 9/1/2024 in patients with T2DM who met these key criteria: evidence of coronary atherosclerosis on CCTA, treatment with ≥1 oral hypoglycaemic agent, and no history of prior coronary interventions. PCAT attenuation was measured in the proximal right coronary artery.Among the three statin intensity groups, patients receiving high-intensity statins (n = 75) had the lowest PCAT attenuation (high-intensity: -75.0 ± 6.8 HU, moderate-intensity: -71.8 ± 8.2 HU, no statin: -71.6 ± 7.4 HU; adjusted p = 0.027). In addition to high-intensity statins, treatment with glucagon-like peptide-1 receptor agonist was independently associated with a lower likelihood of having elevated PCAT attenuation (≥ -70.5 HU), with an odds ratio of 0.344 (95% CI: 0.132-0.900).In patients with T2DM and coronary atherosclerosis, high-intensity statin therapy was associated with lower coronary inflammation. Our findings emphasize the need for aggressive cardiovascular prevention in this high-risk cohort.

    View details for DOI 10.1111/dom.70032

    View details for PubMedID 40826958